Paediatric Committee (PDCO)
Draft Agenda for the meeting on 28-31 May 2024

Chair: Brian Aylward – Vice-Chair: Sylvie Benchetrit

28 May 2024, 14:00 - 19:00, Virtual meeting
29 May 2024, 08:30 - 19:00, Virtual meeting
30 May 2024, 08:30 - 19:00, Virtual meeting
31 May 2024, 08:30 - 13:00, Virtual meeting

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introductions

| 1.1. | Welcome and declarations of interest of members, alternates and experts | 9 |
| 1.2. | Adoption of agenda | 9 |
| 1.3. | Adoption of the minutes | 9 |

## 2. Opinions

### 2.1. Opinions on Products

| 2.1.1. | Ensitrelvir - EMEA-003192-PIP02-23 | 9 |
| 2.1.2. | Lenacapavir - EMEA-002740-PIP02-23 | 9 |
| 2.1.3. | Udonitrectag lysine - Orphan - EMEA-002848-PIP01-20 | 10 |
| 2.1.4. | Mirdametinib - Orphan - EMEA-003525-PIP01-23 | 10 |
| 2.1.5. | Derivative of azabicycloheptane-carboxamide - EMEA-003451-PIP01-23 | 10 |
| 2.1.6. | Indapamide / ramipril - EMEA-003600-PIP01-24 | 10 |
| 2.1.7. | Allogeneic skin-derived ABCBS-positive dermal mesenchymal stromal cells - EMEA-002875-PIP02-24 | 10 |
| 2.1.8. | Autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene - EMEA-003593-PIP01-24 | 11 |
| 2.1.9. | EMEA-003596-PIP01-24 | 11 |
| 2.1.10. | EMEA-003597-PIP01-24 | 11 |
| 2.1.11. | Anti-human LAG-3 mAb, human IgG4 isotype - EMEA-003598-PIP01-24 | 11 |
| 2.1.12. | Autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene - EMEA-003593-PIP02-24 | 11 |
| 2.1.13. | Fulzerasib - EMEA-003594-PIP01-24 | 12 |
| 2.1.14. | HER2 antibody drug conjugate - EMEA-003599-PIP01-24 | 12 |
| 2.1.15. | Recombinant influenza hemagglutinin-strain A (H1N1 subtype) / recombinant influenza hemagglutinin-strain A (H3N2 subtype) / recombinant influenza hemagglutinin-strain B - EMEA-003640-PIP01-24 | 12 |
| 2.1.16. | Diclofenac / thiocolchicoside - EMEA-003611-PIP01-24 | 12 |

### 2.2. Opinions on Compliance Check

| 2.2.1. | Olipudase alfa - EMEA-C-001600-PIP01-13-M02 | 12 |
| 2.2.2. | Tedizolid phosphate - EMEA-C3-001379-PIP01-12-M08 | 13 |
| 2.2.3. | Vanzacaftor / tezacaftor / deutivacaftor - EMEA-C1-003052-PIP01-21 | 13 |
| 2.2.4. | Landiolol (hydrochloride) - EMEA-C-001150-PIP02-13-M05 | 13 |
| 2.2.5. | Fordadistogrene movaparvovec - EMEA-C1-002741-PIP01-20-M02 | 13 |

### 2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

| 2.3.1. | Ralinepag - Orphan - EMEA-002432-PIP02-20-M01 | 13 |
| 2.3.2. | Regadenoson - EMEA-000410-PIP01-08-M07 | 14 |
| 2.3.3. | Pegvaliase - Orphan - EMEA-001951-PIP01-16-M03 | 14 |
2.6.3. Onasemnogene abeparvovec - EMA-C2-002168-PIP01-17-M05
2.4. Opinions on Re-examinations
2.5. Opinions on Review of Granted Waivers
2.6. Finalisation and adoption of Opinions
2.7. Partial Compliance Checks completed by EMA
3. Discussion of applications

3.1. Discussions on Products D90-D60-D30

3.1.1. EMEA-003513-PIP01-23

3.1.2. Mezagatram - EMEA-003502-PIP01-23

3.1.3. Ganaxolone - EMEA-002341-PIP03-23

3.1.4. Vosoritide - EMEA-002033-PIP02-23

3.1.5. A/H1N1, A/H3N2, and B/Victoria and single-stranded 5’ capped mRNA encoding the HAs of the influenza virus strains A/H1N1, A/H3N2, and B/Victoria and the N-terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein - EMEA003521-PIP01-23

3.1.6. Teplizumab - EMEA-000524-PIP02-24

3.1.7. Interleukin-23 receptor antagonist peptide - EMEA-003301-PIP02-24

3.1.8. EMEA-003478-PIP02-24

3.1.9. EMEA-003601-PIP01-24

3.1.10. Bidristrogene xeboparvovec - Orphan - EMEA-003400-PIP02-24

3.1.11. Trastuzumab deruxtecan - EMEA-002978-PIP02-24

3.1.12. 2′-O, 4′-C-methylene-P-thio-adenylyl-(3′–5′)-2′-O, 4′-C-methylene-P-thio-guananyl-(3′–5′)-2′-O, 4′-C-methylene-P-thio-adenylyl-(3′–5′)-2′-deoxy-P-thio-adenylyl-(3′–5′)-2′-deoxy-P-thio-thymidylyl-(3′–5′)-2′-deoxy-P-thio-guananyl-(3′–5′)-2′-deoxy-P-thio-guananyl-(3′–5′)-2′-deoxy-P-thio-adenylyl-(3′–5′)-2′-deoxy-P-thio-adenylyl-(3′–5′)-2′-deoxy-P-thio-cytidylyl-(3′–5′)-2′-deoxy-P-thio-adenylyl-(3′–5′)-2′-deoxy-P-thio-thymidylyl-(3′–5′)-2′-deoxy-P-thio-cytidylyl-(3′–5′)-2′-deoxy-P-thio-uridylyl-(3′–5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-cytidylyl-(3′–5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-uridylyl-(3′–5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-uridylyl-(3′–5′)-2′-O, 4′-C-methyleneguanosine, heptadecasodium salt - Orphan - EMEA-003595-PIP01-24

3.1.13. Gorilla adenovirus vector expressing HPV6 and HPV11 antigens - Orphan - EMEA-003592-PIP01-24


3.1.15. Tadalafil / ambrisentan - EMEA-003617-PIP01-24

3.1.16. Tadalafil / ambrisentan - EMEA-003621-PIP01-24

3.1.17. Luliconazole - EMEA-003604-PIP01-24

3.1.18. Tarumase - EMEA-003616-PIP01-24

3.1.19. Copper (⁶⁴Cu) oxodotreotide - Orphan - EMEA-003610-PIP01-24

3.1.20. 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione - Orphan - EMEA-003618-PIP01-24

3.1.21. Alvlelestat - EMEA-003605-PIP01-24

3.1.22. Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues - EMEA-003420-PIP02-24

3.1.23. Diazoxide choline - Orphan - EMEA-003614-PIP01-24
3.2. Discussions on Compliance Check

3.2.1. Lomitapide - EMEA-C1-001124-PIP01-10-M05 ........................................ 29
3.2.2. Brexpiprazole - EMEA-C3-001185-PIP01-11-M08 ................................. 29
3.2.3. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) / influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / influenza virus type B, Victoria lineage - EMEA-003641-PIP01-24 ...... 28

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Gadopiclenol - EMEA-001949-PIP01-16-M07 .................................................. 29
3.3.2. Gadopiclenol - EMEA-001949-PIP02-18-M05 ............................................. 30
3.3.3. Crinecerfont - Orphan - EMEA-002700-PIP01-19-M02 ............................. 30
3.3.4. Humanised monoclonal antibody Fab fragment - Orphan - EMEA-003253-PIP01-22-M01 .. 30
3.3.5. Navepegritide - Orphan - EMEA-002689-PIP02-23-M01 ............................. 30
3.3.6. Teplizumab - EMEA-000524-PIP01-08-M03 ............................................. 30
3.3.7. Survodutide - EMEA-002942-PIP02-20-M02 ............................................. 31
3.3.8. Tezepelumab - EMEA-001613-PIP03-21-M01 ............................................. 31
3.3.9. Vonoprazan - EMEA-002703-PIP01-19-M01 ............................................. 31
3.3.10. Fitusiran - Orphan - EMEA-001855-PIP01-15-M06 .................................. 31
3.3.11. Osivelotor - EMEA-003241-PIP01-22-M01 ............................................. 31
3.3.12. Narsoplimab - Orphan - EMEA-002479-PIP01-18-M02 ......................... 31
3.3.13. Vadadustat - EMEA-001944-PIP01-16-M05 ............................................. 32
3.3.14. Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded - Orphan - EMEA-002706-PIP01-19-M03 ................................................................. 32
3.3.15. Human normal immunoglobulin - EMEA-001290-PIP01-12-M01 ................................................................. 32
3.3.16. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M07 .................................................................................. 32
3.3.17. Lenacapavir sodium - EMEA-002740-PIP01-19-M01 ................................................................. 32
3.3.18. Pretomanid - Orphan - EMEA-002115-PIP01-17-M06 .............................................................................. 33
3.3.19. Rilpivirine / dolutegravir - EMEA-001750-PIP01-15-M07 ................................................................. 33
3.3.20. Tenofovir alafenamide / emtricitabine / cobicistat / darunavir - EMEA-001825-PIP01-15-M0533 .............................................................................. 33
3.3.21. Cenobamate - EMEA-002563-PIP02-19-M03 .................................................................................. 33
3.3.22. Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes - Orphan - EMEA-001957-PIP02-19-M01 .............................................................................. 33
3.3.23. Efgartigimod alfa - Orphan - EMEA-002597-PIP01-19-M02 .............................................................................. 34
3.3.24. Sodium ((2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl]oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1) - Orphan - EMEA-003344-PIP01-22-M01 .............................................................................. 34
3.3.25. Midostaurin - Orphan - EMEA-000780-PIP01-09-M08 .............................................................................. 34
3.3.26. Venetoclax - Orphan - EMEA-002018-PIP02-16-M06 .................................................................................. 34
3.3.27. Giltekinib (as fumarate) - Orphan - EMEA-002064-PIP01-16-M06 ................................................................. 34
3.3.28. Bupropion hydrochloride / naltrexone hydrochloride - EMEA-001373-PIP01-12-M06 .............................................................................. 35
3.3.29. Ketamine / sufentanil - EMEA-001739-PIP02-16-M03 .................................................................................. 35
3.3.30. Meloxicam / bupivacaine - EMEA-002246-PIP01-17-M05 .............................................................................. 35
3.3.31. Benralizumab - EMEA-001214-PIP04-19-M01 .................................................................................. 35
3.3.32. Donidalorsen - Orphan - EMEA-003112-PIP01-21-M01 .............................................................................. 35
3.3.33. COVID-19 Vaccine (ChAdOx1-S [recombinant]) - EMEA-002862-PIP01-20-M04 .............................................................................. 35
3.3.34. Neisseria meningitidis serogroup B protein-based active substance / recombinant Neisseria meningitidis serogroup B protein 3 / recombinant Neisseria meningitidis serogroup B protein 2 / recombinant Neisseria meningitidis serogroup B protein 1 / Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein / Neisseria Meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein / Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein / Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein - EMEA-003379-PIP01-22-M0136

4. Nominations

4.1. List of submissions of applications with start of procedure 27 May 2024 for Nomination of Rapporteur and Peer reviewer................................................................. 36
4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver ................................................................. 36
4.3. Nominations for other activities .................................................................................. 36

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products........................................ 37
6.1.1. Fezolinetant - EMEA-04-2024 .................................................................................. 37
6.1.2. (PLGA-PEG-PSA) a ligand-presenting nanoparticle - EMEA-05-2024 ......................... 37

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 37

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver ................................................................. 37

8. Annual reports on deferrals 37

9. Organisational, regulatory and methodological matters 37

9.1. Mandate and organisation of the PDCO ......................................................... 37

9.1.1. PDCO membership ............................................................................... 37

9.1.2. Vote by Proxy ......................................................................................... 37

9.1.3. Strategic Review and Learning Meeting (SRLM) - Leuven, Belgium, 16-17 May 2024 .... 38

9.1.4. Scientific Committee Meetings – alternating face-to-face and virtual meetings schedule for 2025 .................................................................. 38

9.2. Coordination with EMA Scientific Committees or CMDh-v .................................. 38

9.2.1. Committee for Medicinal Products for Human Use (CHMP) ................................ 38

9.2.2. Committee on Herbal Medicinal Products (HMPC) - Reflection paper on data recommendations for (traditional) herbal medicinal products in children/adolescents .................. 38

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups .......... 38

9.3.1. Non-clinical Working Party: D30 Products identified ...................................... 38

9.3.2. Paediatric Formulation Operational Expert Group (PFOEG) .............................. 38


9.3.4. Upcoming Innovation Task Force (ITF) meetings ........................................ 39

9.4. Cooperation within the EU regulatory network .................................................. 39

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) ...... 39

9.4.2. European Directorate for the Quality of Medicines & HealthCare (EDQM) ............. 39

9.5. Cooperation with International Regulators ....................................................... 39

9.5.1. Paediatric Cluster Teleconference .................................................................. 39

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee ......................................................... 39

9.7. PDCO work plan .............................................................................................. 39

9.8. Planning and reporting ...................................................................................... 39

9.8.1. EMA Business Pipeline activity and Horizon scanning ................................. 39

10. Any other business 39

10.1. Changes to the labelling of benzyl alcohol in paediatric formulations .................... 39

10.2. Real World Evidence, including DARWIN EU® ............................................... 40

11. Breakout sessions 40

11.1. Internal PDCO Operations .............................................................................. 40
11.2. Paediatric oncology ................................................................. 40
11.3. Neonatology ........................................................................ 40
11.4. HIV ....................................................................................... 40

12. Explanatory notes 41
1. **Introductions**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PDCO plenary session to be held 28-31 May 2024. See May 2024 PDCO minutes (to be published post June 2024 PDCO meeting).

1.2. **Adoption of agenda**

PDCO agenda for 28-31 May 2024.

1.3. **Adoption of the minutes**

PDCO minutes for 23-26 April 2024.

2. **Opinions**

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. **Opinions on Products**

2.1.1. **Ensitrelvir - EMEA-003192-PIP02-23**

Treatment of coronavirus disease 2019 (COVID-19)

Day 120 opinion

**Action**: For adoption

Infectious Diseases

2.1.2. **Lenacapavir - EMEA-002740-PIP02-23**

Prevention of human immunodeficiency virus (HIV-1) infection

Day 120 opinion

**Action**: For adoption

Infectious Diseases

*Note: Withdrawal request received on 21 May 2024*
2.1.3. Udonitrectag lysine - Orphan - EMEA-002848-PIP01-20

Recordati Rare Diseases; Treatment of neurotrophic keratitis
Day 120 opinion

**Action:** For adoption

Ophthalmology

*Note: Withdrawal request received on 21 May 2024*

2.1.4. Mirdametinib - Orphan - EMEA-003525-PIP01-23

Springworks Therapeutics Ireland Limited; Treatment of neurofibromatosis type 1 - plexiform neurofibroma / Treatment of neurofibromatosis type 1
Day 120 opinion

**Action:** For adoption

Other

2.1.5. Derivative of azabicycloheptane-carboxamide - EMEA-003451-PIP01-23

Treatment of bronchiectasis
Day 120 opinion

**Action:** For adoption

Pneumology - Allergology

2.1.6. Indapamide / ramipril - EMEA-003600-PIP01-24

Treatment of hypertension
Day 60 opinion

**Action:** For adoption

Cardiovascular Diseases

2.1.7. Allogeneic skin-derived ABCB5-positive dermal mesenchymal stromal cells - EMEA-002875-PIP02-24

Treatment of venous leg ulcer
Day 60 opinion

**Action:** For adoption

Dermatology
2.1.8. **Autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene - EMEA-003593-PIP01-24**

Treatment of systemic light chain amyloidosis

**Day 60 opinion**

**Action**: For adoption

Endocrinology-Gynaecology-Fertility-Metabolism

2.1.9. **EMEA-003596-PIP01-24**

Treatment of mature B-cell neoplasms

**Day 60 opinion**

**Action**: For adoption

Oncology

2.1.10. **EMEA-003597-PIP01-24**

Treatment of pancreatic cancer

**Day 60 opinion**

**Action**: For adoption

Oncology

2.1.11. **Anti-human LAG-3 mAb, human IgG4 isotype - EMEA-003598-PIP01-24**

Treatment of lung cancer

**Day 60 opinion**

**Action**: For adoption

Oncology

2.1.12. **Autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene - EMEA-003593-PIP02-24**

Treatment of multiple myeloma

**Day 60 opinion**

**Action**: For adoption

Oncology
2.1.13. Fulzerasib - EMEA-003594-PIP01-24

Treatment of colorectal cancer
Day 60 opinion
**Action:** For adoption
Oncology

2.1.14. HER2 antibody drug conjugate - EMEA-003599-PIP01-24

Treatment of breast cancer / Treatment of endometrial cancer
Day 60 opinion
**Action:** For adoption
Oncology

2.1.15. Recombinant influenza hemagglutinin-strain A (H1N1 subtype) / recombinant influenza hemagglutinin-strain A (H3N2 subtype) / recombinant influenza hemagglutinin-strain B - EMEA-003640-PIP01-24

Prevention of influenza disease
Day 30 opinion
**Action:** For adoption
Vaccines

2.1.16. Diclofenac / thiocolchicoside - EMEA-003611-PIP01-24

Treatment of musculoskeletal and connective tissue pain and discomfort
Day 30 opinion
**Action:** For adoption
Pain

2.2. Opinions on Compliance Check

2.2.1. Olipudase alfa - EMEA-C-001600-PIP01-13-M02

Sanofi B.V.; Treatment of Niemann-Pick disease
Day 60 opinion
**Action:** For adoption
Endocrinology-Gynaecology-Fertility-Metabolism
2.2.2. **Tedizolid phosphate - EMEA-C3-001379-PIP01-12-M08**

MSD Europe Belgium SRL; Treatment of acute bacterial skin and skin structure infections

Day 60 letter

**Action:** For adoption

Infectious Diseases

2.2.3. **Vanzacaftor / tezacaftor / deutivacaftor - EMEA-C1-003052-PIP01-21**

Vertex Pharmaceuticals (Ireland) Limited; Treatment of cystic fibrosis

Day 60 letter

**Action:** For adoption

Pneumology – Allergology

2.2.4. **Landiolol (hydrochloride) - EMEA-C-001150-PIP02-13-M05**

AOP Orphan Pharmaceuticals GmbH; Treatment of supraventricular arrhythmias

Day 30 opinion

**Action:** For adoption

Cardiovascular Diseases

2.2.5. **Fordadistrogene movaparvovec - EMEA-C1-002741-PIP01-20-M02**

Pfizer Europe MA EEIG; Treatment of Duchenne muscular dystrophy

Day 60 letter

**Action:** For adoption

Neurology

2.3. **Opinions on Modification of an Agreed Paediatric Investigation Plan**

2.3.1. **Ralinepag - Orphan - EMEA-002432-PIP02-20-M01**

United Therapeutics Corporation; Treatment of pulmonary arterial hypertension

Day 60 opinion

**Action:** For adoption

Cardiovascular Diseases
2.3.2. Regadenoson - EMEA-000410-PIP01-08-M07

GE Healthcare AS; Diagnosis of myocardial perfusion disturbances
Day 60 opinion
Action: For adoption
Diagnostic / Cardiovascular Diseases

2.3.3. Pegvaliase - Orphan - EMEA-001951-PIP01-16-M03

BioMarin International Limited; Treatment of hyperphenylalaninaemia
Day 60 opinion
Action: For adoption
Endocrinology-Gynaecology-Fertility-Metabolism

2.3.4. RAAV8-hUGT1A1 - Orphan - EMEA-002021-PIP01-16-M01

GENETHON; Treatment of Crigler-Najjar syndrome
Day 60 opinion
Action: For adoption
Endocrinology-Gynaecology-Fertility-Metabolism

2.3.5. Vedolizumab - EMEA-000645-PIP01-09-M09

Takeda Pharma A/S; Treatment of ulcerative colitis / Treatment of Crohn's disease
Day 60 opinion
Action: For adoption
Gastroenterology-Hepatology

2.3.6. Luspatercept - Orphan - EMEA-001521-PIP01-13-M07

Bristol-Myers Squibb Pharma EEIG; Treatment of myelodysplastic syndromes / Treatment of beta-thalassaemia
Day 60 opinion
Action: For adoption
Haematology-Hemostaseology

2.3.7. Vonicog alfa - EMEA-001164-PIP01-11-M08

Baxalta Innovations GmBH; Treatment of Von Willebrand disease
Day 60 opinion

**Action**: For adoption

Haematology-Hemostaseology

### 2.3.8. Sarilumab - EMEA-001045-PIP01-10-M04

Sanofi Winthrop Industrie; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

Day 60 opinion

**Action**: For adoption

Immunology-Rheumatology-Transplantation

### 2.3.9. Tofacitinib citrate - EMEA-000576-PIP01-09-M16

Pfizer Europe MA EEIG; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Day 60 opinion

**Action**: For adoption

Immunology-Rheumatology-Transplantation

### 2.3.10. Islatravir / doravirine - EMEA-002707-PIP01-19-M02

MSD Europe Belgium SRL; Treatment of human immunodeficiency virus-1 (HIV-1) infection

Day 60 opinion

**Action**: For adoption

Infectious Diseases

### 2.3.11. Lamivudine / dolutegravir - EMEA-001940-PIP01-16-M06

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

**Action**: For adoption

Infectious Diseases

### 2.3.12. Tenofovir disoproxil fumarate / lamivudine / doravirine - EMEA-001695-PIP01-14-M06

MSD Europe Belgium SRL; Treatment of human immunodeficiency virus-1 (HIV-1) infection

Day 60 opinion
**Action**: For adoption

Infectious Diseases

2.3.13. **Ublituximab - EMEA-002889-PIP02-20-M01**

Neuraxpharm Pharmaceuticals, S.L.; Treatment of multiple sclerosis

Day 60 opinion

**Action**: For adoption

Neurology

2.3.14. **Brexucabtagene autoleucel - Orphan - EMEA-001862-PIP01-15-M04**

Kite Pharma EU B.V.; Treatment of acute lymphoblastic leukaemia

Day 60 opinion

**Action**: For adoption

Oncology

2.3.15. **Dostarlimab - EMEA-002463-PIP01-18-M02**

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies)

Day 60 opinion

**Action**: For adoption

Oncology

2.3.16. **Epcoritamab - Orphan - EMEA-002907-PIP01-20-M03**

AbbVie Ltd; Treatment of mature B-cell lymphoma

Day 60 opinion

**Action**: For adoption

Oncology

2.3.17. **Niraparib tosylate monohydrate - EMEA-002268-PIP02-18-M02**

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies)

Day 60 opinion

**Action**: For adoption

Oncology
<table>
<thead>
<tr>
<th>2.3.18.</th>
<th><strong>Ribociclib - EMEA-002765-PIP02-21-M01</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Europharm Limited; Treatment of neuroblastoma</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption</td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.3.19.</th>
<th><strong>Botaretigene sparoparvovec - Orphan - EMEA-002827-PIP01-20-M03</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen-Cilag International NV Turnhoutseweg 30; Treatment of retinitis pigmentosa</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption</td>
<td></td>
</tr>
<tr>
<td>Ophthalmology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.3.20.</th>
<th><strong>Iptacopan - Orphan - EMEA-002705-PIP01-19-M02</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Europharm Limited; Treatment of C3 glomerulopathy</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.3.21.</th>
<th><strong>Mexiletine hydrochloride - Orphan - EMEA-002012-PIP01-16-M05</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lupin Europe GmbH; Treatment of myotonic disorders</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.3.22.</th>
<th><strong>Setrusumab - Orphan - EMEA-002169-PIP01-17-M03</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mereo BioPharma Ireland Limited; Treatment of osteogenesis imperfecta</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.3.23.</th>
<th><strong>Xylitol / procaine hydrochloride / magnesium sulphate heptahydrate / potassium chloride - EMEA-001171-PIP01-11-M03</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MIT Gesundheit GmbH; Cardioplegia</td>
<td></td>
</tr>
<tr>
<td>Day 60 opinion</td>
<td></td>
</tr>
</tbody>
</table>
**Action**: For adoption

**Other**

### 2.3.24. *Dermatophagoides farinae* extracts - EMEA-000834-PIP01-10-M01

Allergopharma GmbH & Co. KG; Treatment of allergic asthma / Treatment of allergic rhinitis / rhinoconjunctivitis

Day 60 opinion

**Action**: For adoption

Pneumology - Allergology

### 2.3.25. *Dermatophagoides pteronyssinus* extracts 100% - EMEA-000835-PIP01-10-M01

Allergopharma GmbH & Co. KG; Treatment of allergic asthma / Treatment of allergic rhinitis / rhinoconjunctivitis

Day 60 opinion

**Action**: For adoption

Pneumology - Allergology

### 2.3.26. *Dermatophagoides pteronyssinus* / *Dermatophagoides farinae* extracts (50%/50%) - EMEA-000836-PIP01-10-M01

Allergopharma GmbH & Co. KG; Treatment of allergic rhinitis / rhinoconjunctivitis / Treatment of allergic asthma

Day 60 opinion

**Action**: For adoption

Pneumology - Allergology

### 2.3.27. Cariprazine hydrochloride - EMEA-001652-PIP01-14-M06

Gedeon Richter Plc.; Treatment of schizophrenia

Day 60 opinion

**Action**: For adoption

Psychiatry

### 2.3.28. Ravulizumab (ALXN1210) - EMEA-001943-PIP02-20-M03

Alexion Europe SAS; Treatment in haematopoietic stem cell transplant

Day 60 opinion

**Action**: For adoption
Uro-nephrology / Haematology-Hemostaseology

Note: Withdrawal request received on 14 May 2024

2.3.29. NVX-CoV2373 - EMEA-002941-PIP01-20-M05

Novavax CZ, a.s.; Prevention of coronavirus disease 2019 (COVID-19)
Day 60 opinion

Action: For adoption

Vaccines

2.3.30. COVID-19 Vaccine, recombinant, adjuvanted - EMEA-003191-PIP01-22-M01

HIPRA Human Health S.L.U.; Prevention of coronavirus disease 2019 (COVID-19)
Day 60 opinion

Action: For adoption

Vaccines

2.3.31. Recombinant influenza hemagglutinin-strain B (Yamagata lineage) / recombinant influenza hemagglutinin-strain B (Victoria lineage) / recombinant influenza hemagglutinin-strain A (H3N2 subtype) / recombinant influenza hemagglutinin-strain A (H1N1 subtype) - EMEA-002418-PIP01-18-M04

Sanofi Pasteur; Prevention of influenza disease
Day 30 opinion

Action: For adoption

Vaccines

2.3.32. Ibrexafungerp (citrate) - EMEA-002535-PIP03-19-M01

SCYNEXIS, Inc.; Treatment of vulvovaginal candidiasis / Prevention of recurrent vulvovaginal candidiasis
Day 30 opinion

Action: For adoption

Infectious Diseases

2.3.33. Gefurulimab - EMEA-003302-PIP01-22-M01

Alexion Europe SAS; Treatment of myasthenia gravis
Day 30 opinion

Action: For adoption
2.4. **Opinions on Re-examinations**

No item

2.5. **Opinions on Review of Granted Waivers**

No item

2.6. **Finalisation and adoption of Opinions**

No item

2.7. **Partial Compliance Checks completed by EMA**

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. **Onasemnogene abeparvovec - EMEA-C2-002168-PIP01-17-M05**

Novartis Europharm Limited; Treatment of spinal muscular atrophy

Day 30 letter

**Action**: For information

Neurology

2.7.2. **Gadoquatrane - EMEA-C1-002778-PIP01-20-M01**

Bayer AG; Diagnosis by evaluation of any known or suspected clinical condition with contrast enhanced magnetic resonance imaging

Day 30 letter

**Action**: For information

Diagnostic

2.7.3. **Ustekinumab - EMEA-C2-000311-PIP04-13-M06**

Janssen-Cilag International NV; Treatment of Crohn's disease

Day 30 letter

**Action**: For information

Gastroenterology-Hepatology
2.7.4.  Acetyl-L-leucine - EMEA-C1-002796-PIP01-20-M02

IntraBio Ltd; Treatment of Niemann-Pick disease type C
Day 30 letter
Action: For information
Neurology

2.7.5.  Iptacopan - EMEA-C1-002705-PIP02-19-M01

Novartis Europharm Limited; Treatment of IgA nephropathy
Day 30 letter
Action: For information
Uro-nephrology

3.  Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1.  Discussions on Products D90-D60-D30

3.1.1.  EMEA-003513-PIP01-23

Treatment of coeliac disease
Day 90 discussion
Action: For discussion
Gastroenterology-Hepatology

3.1.2.  Mezagitamab - EMEA-003502-PIP01-23

Treatment of immune thrombocytopenia (ITP)
Day 90 discussion
Action: For discussion
Haematology-Hemostaseology

3.1.3.  Ganaxolone - EMEA-002341-PIP03-23

Treatment of refractory status epilepticus
Day 90 discussion
### 3.1.4. Vosoritide - EMEA-002033-PIP02-23

Treatment of hypochondroplasia

**Action**: For discussion

**Neurology**

### 3.1.5. A/H1N1, A/H3N2, and B/Victoria and single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A/H1N1, A/H3N2, and B/Victoria and the N-terminal domain (NTD) and receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein - EMEA-003521-PIP01-23

Prevention of influenza and coronavirus disease 2019 (COVID-19)

**Action**: For discussion

**Other**

### 3.1.6. Teplizumab - EMEA-000524-PIP02-24

Prevention or delay of (clinical) type 1 diabetes mellitus

**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism**

### 3.1.7. Interleukin-23 receptor antagonist peptide - EMEA-003301-PIP02-24

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

**Action**: For discussion

**Immunology-Rheumatology-Transplantation**

### 3.1.8. EMEA-003478-PIP02-24

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism**
**Action:** For discussion

Immunology-Rheumatology-Transplantation

3.1.9. **EMEA-003601-PIP01-24**

Prevention of *Clostridioides difficile* infection

Day 60 discussion

**Action:** For discussion

Infectious Diseases

3.1.10. **Bidridistrogene xeboparvovec - Orphan - EMEA-003400-PIP02-24**

Sarepta Therapeutics Ireland; Treatment of limb-girdle muscular dystrophy

Day 60 discussion

**Action:** For discussion

Neurology

3.1.11. **Trastuzumab deruxtecan - EMEA-002978-PIP02-24**

Treatment of all conditions in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 60 discussion

**Action:** For discussion

Oncology

3.1.12. **2′-O, 4′-C-methylene-P-thio-adenylyl-(3′→5′)-2′-O, 4′-C-methylene-P-thio-guanylyl-(3′→5′)-2′-O, 4′-C-methylene-P-thio-adenylyl-(3′→5′)-2′-deoxy-P-thio-thymidylyl-(3′→5′)-2′-deoxy-P-thio-guanylyl-(3′→5′)-2′-deoxy-P-thio-guanylyl-(3′→5′)-2′-deoxy-P-thio-cytidylyl-(3′→5′)-2′-deoxy-P-thio-adenylyl-(3′→5′)-2′-deoxy-P-thio-cytidylyl-(3′→5′)-2′-deoxy-P-thio-guanylyl-(3′→5′)-2′-deoxy-P-thio-cytidylyl-(3′→5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-cytidylyl-(3′→5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-uridylyl-(3′→5′)-2′-O, 4′-C-methylene-guanosine, heptadecasodium salt - Orphan - EMEA-003595-PIP01-24**

Ultragenyx Germany GmBH; Treatment of Angelman syndrome

Day 60 discussion

**Action:** For discussion

Other
3.1.13.  **Gorilla adenovirus vector expressing HPV6 and HPV11 antigens - Orphan - EMEA-003592-PIP01-24**

Precigen, Inc.; Treatment respiratory papillomatosis
Day 60 discussion

**Action:** For discussion

Oto-rhino-laryngology

3.1.14.  **Lebrikizumab - EMEA-002536-PIP03-24**

Treatment of perennial allergic rhinitis
Day 60 discussion

**Action:** For discussion

Pneumology - Allergology

3.1.15.  **Tadalafil / ambrisentan - EMEA-003617-PIP01-24**

Treatment of pulmonary arterial hypertension
Day 30 discussion

**Action:** For discussion

Cardiovascular Diseases

3.1.16.  **Tadalafil / ambrisentan - EMEA-003621-PIP01-24**

Treatment of pulmonary arterial hypertension
Day 30 discussion

**Action:** For discussion

Cardiovascular Diseases

3.1.17.  **Luliconazole - EMEA-003604-PIP01-24**

Treatment of onychomycosis
Day 30 discussion

**Action:** For discussion

Dermatology

3.1.18.  **Tarumase - EMEA-003616-PIP01-24**

Treatment of chronic wounds
Day 30 discussion
**3.1.19. Copper (⁶⁴Cu) oxodotreotide - Orphan - EMEA-003610-PIP01-24**

Curium Pet France; Diagnosis of neuroendocrine neoplasms
Day 30 discussion
**Action**: For discussion

**Diagnostic**

**3.1.20. 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione - Orphan - EMEA-003618-PIP01-24**

Abliva AB; Treatment of primary mitochondrial disease
Day 30 discussion
**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism**

**3.1.21. Alvelestat - EMEA-003605-PIP01-24**

Treatment of alpha-1 antitrypsin deficiency
Day 30 discussion
**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism**

**3.1.22. Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues - EMEA-003420-PIP02-24**

Treatment of severe hypertriglyceridaemia (SHTG)
Day 30 discussion
**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism**

**3.1.23. Diazoxide choline - Orphan - EMEA-003614-PIP01-24**

Solenoid Therapeutics Europe Ltd.; Treatment of Prader-Willi syndrome
Day 30 discussion
**Action**: For discussion

**Endocrinology-Gynaecology-Fertility-Metabolism / Psychiatry / Neurology**
3.1.24. **Pegozafermin - EMEA-003619-PIP01-24**

Treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Day 30 discussion

**Action**: For discussion

Gastroenterology-Hepatology

3.1.25. **Inobrodib - EMEA-003622-PIP01-24**

Treatment of multiple myeloma

Day 30 discussion

**Action**: For discussion

Haematology-Hemostaseology

3.1.26. **Telitacicept - EMEA-002824-PIP02-24**

Treatment of myasthenia gravis

Day 30 discussion

**Action**: For discussion

Immunology-Rheumatology-Transplantation

3.1.27. **Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein - EMEA-003620-PIP01-24**

Treatment of Wiskott-Aldrich syndrome

Day 30 discussion

**Action**: For discussion

Immunology-Rheumatology-Transplantation / Haematology-Hemostaseology

3.1.28. **EMEA-003609-PIP01-24**

Treatment of respiratory tract disease caused by human respiratory syncytial virus

Day 30 discussion

**Action**: For discussion

Infectious Diseases

3.1.29. **EMEA-003306-PIP02-24**

Treatment of human respiratory syncytial virus (RSV)

Day 30 discussion
Action: For discussion
Infectious Diseases

3.1.30. **EMEA-003615-PIP01-24**

Treatment of Prader Willi syndrome
Day 30 discussion
Action: For discussion
Neurology

3.1.31. **Frexalimab - EMEA-002945-PIP04-24**

Treatment of multiple sclerosis
Day 30 discussion
Action: For discussion
Neurology

3.1.32. **Acasunlimab - EMEA-003606-PIP01-24**

Treatment of lung cancer
Day 30 discussion
Action: For discussion
Oncology

3.1.33. **Buparlisib - EMEA-003607-PIP01-24**

Treatment of head and neck epithelial malignant neoplasms
Day 30 discussion
Action: For discussion
Oncology

3.1.34. **Gedatolisib - EMEA-003612-PIP01-24**

Treatment of children with solid malignancies / Treatment of haematologic malignancies / Treatment of central nervous system malignancies
Day 30 discussion
Action: For discussion
Oncology
3.1.35.  
**Ifinatamab deruxtecan - Orphan - EMEA-003613-PIP01-24**

Daiichi Sankyo Europe GmbH; Treatment of lung cancer
Day 30 discussion
**Action**: For discussion
Oncology

3.1.36.  
**Letetresgene autoleucel - Orphan - EMEA-002476-PIP03-24**

Adaptimmune B. V.; Treatment of soft tissue sarcoma
Day 30 discussion
**Action**: For discussion
Oncology

3.1.37.  
**Rocatinlimab - EMEA-002886-PIP03-24**

Treatment of asthma
Day 30 discussion
**Action**: For discussion
Pneumology - Allergology

3.1.38.  
**Sargramostim - EMEA-003568-PIP02-24**

Treatment of autoimmune pulmonary alveolar proteinosis (aPAP)
Day 30 discussion
**Action**: For discussion
Pneumology - Allergology

3.1.39.  
**Iloperidone - EMEA-000995-PIP02-24**

Treatment of bipolar disorder
Day 30 discussion
**Action**: For discussion
Psychiatry

3.1.40.  
**Purified antigen fractions of inactivated split virion influenza virus type A, H1N1 / influenza virus type A, H3N2 / influenza virus type B, Victoria lineage - EMEA-003641-PIP01-24**

Prevention of influenza infection
Day 30 discussion

**Action:** For discussion

Vaccines

### 3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

#### 3.2.1. Lomitapide - EMEA-C1-001124-PIP01-10-M05

Amryt Pharmaceuticals DAC; Treatment of heterozygous and homozygous familial hypercholesterolaemia

Day 30 discussion

**Action:** For discussion

Endocrinology-Gynaecology-Fertility-Metabolism

#### 3.2.2. Brexpiprazole - EMEA-C3-001185-PIP01-11-M08

Otsuka Pharmaceutical Development & commercialisation Europe GmbH; Treatment of schizophrenia

Day 30 discussion

**Action:** For discussion

Psychiatry

#### 3.2.3. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) / influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) - EMEA-C-003623-PIP01-24

Seqirus Netherlands B.V.; Prevention of influenza infection

Day 30 discussion

**Action:** For discussion

Vaccines

### 3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

#### 3.3.1. Gadopiclenol - EMEA-001949-PIP01-16-M07

Guerbet; Detection and visualisation of disorders or lesions with suspected abnormal
vascularity in various body regions for diagnostic purposes

Day 30 discussion

**Action**: For discussion

Diagnostic

### 3.3.2. Gadopiclenol - EMEA-001949-PIP02-18-M05

Guerbet; Detection and visualisation of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes

Day 30 discussion

**Action**: For discussion

Diagnostic

### 3.3.3. Crinecerfont - Orphan - EMEA-002700-PIP01-19-M02

Neurocrine Therapeutics Ltd.; Treatment of congenital adrenal hyperplasia

Day 30 discussion

**Action**: For discussion

Endocrinology-Gynaecology-Fertility-Metabolism

### 3.3.4. Humanised monoclonal antibody Fab fragment - Orphan - EMEA-003253-PIP01-22-M01

Sanofi B.V; Treatment of achondroplasia

Day 30 discussion

**Action**: For discussion

Endocrinology-Gynaecology-Fertility-Metabolism

### 3.3.5. Navepegritide - Orphan - EMEA-002689-PIP02-23-M01

Ascendis Pharma Growth Disorders A/S; Treatment of achondroplasia

Day 30 discussion

**Action**: For discussion

Endocrinology-Gynaecology-Fertility-Metabolism

### 3.3.6. Teplizumab - EMEA-000524-PIP01-08-M03

Sanofi Winthrop Industrie; Treatment of type 1 diabetes mellitus

Day 30 discussion

**Action**: For discussion
3.3.7. **Survodutide - EMEA-002942-PIP02-20-M02**

Boehringer Ingelheim International GmbH; Treatment of obesity

Day 30 discussion

**Action:** For discussion

Gastroenterology-Hepatology

3.3.8. **Tezepelumab - EMEA-001613-PIP03-21-M01**

AstraZeneca AB; Treatment of eosinophilic esophagitis

Day 30 discussion

**Action:** For discussion

Gastroenterology-Hepatology

3.3.9. **Vonoprazan - EMEA-002703-PIP01-19-M01**

Phathom Pharmaceuticals, Inc.; Treatment of gastroesophageal reflux disease (GORD) / Treatment of *Helicobacter pylori* infection

Day 30 discussion

**Action:** For discussion

Gastroenterology-Hepatology

3.3.10. **Fitusiran - Orphan - EMEA-001855-PIP01-15-M06**

Sanofi B.V.; Treatment of haemophilia B / Treatment of haemophilia A

Day 30 discussion

**Action:** For discussion

Haematology-Hemostaseology

3.3.11. **Osivelotor - EMEA-003241-PIP01-22-M01**

Pfizer Europe MA EEIG; Treatment of sickle cell disease

Day 30 discussion

**Action:** For discussion

Haematology-Hemostaseology

3.3.12. **Narsoplimab - Orphan - EMEA-002479-PIP01-18-M02**

Omeros Ireland Limited; Treatment in haematopoietic stem cell transplantation
Day 30 discussion

**Action**: For discussion

Haematology-Hemostaseology

### 3.3.13. Vadadustat - EMEA-001944-PIP01-16-M05

Medice Arzneimittel Pütter GmbH & Co KG; Treatment of anaemia due to chronic disorders

Day 30 discussion

**Action**: For discussion

Haematology-Hemostaseology

### 3.3.14. Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded - Orphan - EMEA-002706-PIP01-19-M03

medac Gesellschaft für klinische Spezialpräparate mbH; Treatment of acute graft-versus-host-disease

Day 30 discussion

**Action**: For discussion

Immunology-Rheumatology-Transplantation

### 3.3.15. Human normal immunoglobulin - EMEA-001290-PIP01-12-M01

LFB Biotechnologies; Treatment of primary immunodeficiency (PID)

Day 30 discussion

**Action**: For discussion

Immunology-Rheumatology-Transplantation

### 3.3.16. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M07

Basilea Pharmaceutica Deutschland GmbH; Treatment of pneumonia

Day 30 discussion

**Action**: For discussion

Infectious Diseases

### 3.3.17. Lenacapavir sodium - EMEA-002740-PIP01-19-M01

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

**Action**: For discussion
Infectious Diseases

3.3.18. Pretomanid - Orphan - EMEA-002115-PIP01-17-M06

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 30 discussion

Action: For discussion

Infectious Diseases

3.3.19. Rilpivirine / dolutegravir - EMEA-001750-PIP01-15-M07

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Day 30 discussion

Action: For discussion

Infectious Diseases

3.3.20. Tenofovir alafenamide / emtricitabine / cobicistat / darunavir - EMEA-001825-PIP01-15-M05

Janssen-Cilag International NV; Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Day 30 discussion

Action: For discussion

Infectious Diseases

3.3.21. Cenobamate - EMEA-002563-PIP02-19-M03

Angelini Pharma S.p.A; Treatment of focal onset seizures (FOS) / Treatment of primary generalised tonic clonic seizures (PGTC)

Day 30 discussion

Action: For discussion

Neurology

3.3.22. Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes - Orphan - EMEA-001957-PIP02-19-M01

Quince Therapeutics, S.p.A.; Treatment of ataxia telangiectasia

Day 30 discussion

Action: For discussion

Neurology
3.3.23. **Efgartigimod alfa - Orphan - EMEA-002597-PIP01-19-M02**

argenx BV; Treatment of generalised myasthenia gravis

Day 30 discussion

**Action**: For discussion

Neurology

3.3.24. **Sodium ((2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl)oxy)methyl hydrogen phosphate-2-amino-2-((hydroxymethyl)propane-1,3-diol (1/1/1) - Orphan - EMEA-003344-PIP01-22-M01**

AbbVie Limited; Treatment of vanishing white matter disease

Day 30 discussion

**Action**: For discussion

Neurology

3.3.25. **Midostaurin - Orphan - EMEA-000780-PIP01-09-M08**

Novartis Europharm Limited; Treatment of acute myeloid leukaemia / Treatment of malignant mastocytosis / Treatment of mast cell leukaemia

Day 30 discussion

**Action**: For discussion

Oncology

3.3.26. **Venetoclax - Orphan - EMEA-002018-PIP02-16-M06**

Abbvie Ltd; Treatment of haematopoietic and lymphoid malignant neoplasms / Treatment of solid tumour malignant neoplasms

Day 30 discussion

**Action**: For discussion

Oncology

3.3.27. **Gilteritinib (as fumarate) - Orphan - EMEA-002064-PIP01-16-M06**

Astellas Pharma Europe B.V.; Treatment of acute myeloid leukaemia

Day 30 discussion

**Action**: For discussion

Oncology / Haematology-Hemostaseology
3.3.28. Bupropion hydrochloride / naltrexone hydrochloride - EMEA-001373-PIP01-12-M06

Orexigen Therapeutics Ireland Limited; Treatment of obesity
Day 30 discussion
Action: For discussion
Other

3.3.29. Ketamine / sufentanil - EMEA-001739-PIP02-16-M03

Cessatech A/S; Treatment of acute pain
Day 30 discussion
Action: For discussion
Pain

3.3.30. Meloxicam / bupivacaine - EMEA-002246-PIP01-17-M05

Heron Therapeutics B.V.; Treatment of acute postoperative pain
Day 30 discussion
Action: For discussion
Pain

3.3.31. Benralizumab - EMEA-001214-PIP04-19-M01

AstraZeneca AB; Treatment of hypereosinophilic syndrome
Day 30 discussion
Action: For discussion
Pneumology - Allergology

3.3.32. Donidalorsen - Orphan - EMEA-003112-PIP01-21-M01

Otsuka Pharmaceutical Netherlands B.V.; Treatment of hereditary angioedema
Day 30 discussion
Action: For discussion
Pneumology - Allergology

3.3.33. COVID-19 Vaccine (ChAdOx1-S [recombinant]) - EMEA-002862-PIP01-20-M04

AstraZeneca AB; Prevention of coronavirus disease 2019 (COVID-19)
Day 30 discussion
Action: For discussion
Vaccines

3.3.34. *Neisseria meningitidis* serogroup B protein-based active substance / recombinant *Neisseria meningitidis* serogroup B protein 3 / recombinant *Neisseria meningitidis* serogroup B protein 2 / recombinant *Neisseria meningitidis* serogroup B protein 1 / *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria Meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein - EMEA-003379-PIP01-22-M01

Sanofi Pasteur; Prevention of meningococcal disease (serogroups A, B, C, W and Y)

Day 30 discussion

**Action:** For discussion

Vaccines

4. **Nominations**

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. **List of submissions of applications with start of procedure 27 May 2024 for Nomination of Rapporteur and Peer reviewer**

**Action:** For adoption

4.2. **Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver**

**Action:** For adoption

4.3. **Nominations for other activities**

**Action:** For adoption

5. **Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction**

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

6. **Discussion on the applicability of class waivers**

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.
6.1. **Discussions on the applicability of class waiver for products**

6.1.1. **Fezolinetant - EMEA-04-2024**

Astellas Pharma Europe B.V.; The classes of androgen receptor modulator, of oestrogen receptor modulator, of growth and sex hormone as well as their releasing or inhibiting factors, and of sex hormone-metabolism modulator medicinal products for treatment of breast malignant neoplasms.

Treatment of moderate to severe vasomotor symptoms in women with breast cancer on adjuvant endocrine therapy.

**Action:** For adoption

6.1.2. **(PLGA-PEG-PSA) a ligand-presenting nanoparticle - EMEA-05-2024**

Aviceda Therapeutics, Inc.; All classes of medicinal products for treatment of age-related macular degeneration and diabetic macular oedema.

Treatment of geographic atrophy secondary to age-related macular degeneration

**Action:** For adoption

7. **Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver**

7.1. **Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver**

No item

8. **Annual reports on deferrals**

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. **Organisational, regulatory and methodological matters**

9.1. **Mandate and organisation of the PDCO**

9.1.1. **PDCO membership**

**Action:** For information
9.1.2. Vote by Proxy

**Action**: For information

9.1.3. Strategic Review and Learning Meeting (SRLM) - Leuven, Belgium, 16-17 May 2024

Update on the SRLM meeting held in Leuven during the Belgium Presidency

PDCO member: Karen van Malderen

**Action**: For information

9.1.4. Scientific Committee Meetings – alternating face-to-face and virtual meetings schedule for 2025

**Action**: For information

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

**Action**: For information

9.2.2. Committee on Herbal Medicinal Products (HMPC) - Reflection paper on data recommendations for (traditional) herbal medicinal products in children/adolescents

PDCO Chair: Brian Aylward

**Action**: For information

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

**Action**: For information

9.3.2. Paediatric Formulation Operational Expert Group (PFOEG)

PDCO member: Brian Aylward (*ad interim*)

**Action**: For information


No item
9.3.4. **Upcoming Innovation Task Force (ITF) meetings**

*Action:* For information

9.4. **Cooperation within the EU regulatory network**

9.4.1. **European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)**

No item

9.4.2. **European Directorate for the Quality of Medicines & HealthCare (EDQM)**

Feedback from the Paediatric Formulary meeting held in Strasbourg (FR) on 5-6 March 2024

PDCO member: Siri Wang

*Action:* For information

9.5. **Cooperation with International Regulators**

9.5.1. **Paediatric Cluster Teleconference**

*Action:* For information

9.6. **Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee**

No item

9.7. **PDCO work plan**

No item

9.8. **Planning and reporting**

9.8.1. **EMA Business Pipeline activity and Horizon scanning**

No item

10. **Any other business**

10.1. **Changes to the labelling of benzyl alcohol in paediatric formulations**

PDCO member: Karen Van Malderen
**10.2. Real World Evidence, including DARWIN EU®**

Scope: Feedback on the February 2024 patient registry workshop, including recommendations/actions, and impact on PDCO

**Action:** For information

---

**11. Breakout sessions**

11.1. **Internal PDCO Operations**

**Action:** For discussion on Tuesday, 12:00 - 13:00

11.2. **Paediatric oncology**

**Action:** For discussion on Tuesday, 13:00 - 14:00

11.3. **Neonatology**

**Action:** For discussion on Wednesday, 13:00 - 14:00

11.4. **HIV**

**Action:** For discussion on Thursday, 13:00 - 14:00
The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

**Paediatric investigation plan (PIP)** *(section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)*

A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

**Compliance checks** *(section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)*

A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

**Modification of an Agreed Paediatric Investigation Plan** *(section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)*

The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate. In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

**Class waiver** *(section 6 Discussion on the applicability of class waiver)*

As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived. For more information on the classes of diseases subject to waivers, see [class waivers](#).

**Annual reports on deferrals** *(section 8)*

If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

For a list of acronyms and abbreviations, see: [Abbreviations used in EMA scientific committees & CMD documents and in relation to EMA's regulatory activities](#).

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)